TB206-001 / Twist Biosci - LARVOL DELTA

Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor (Businesswire) - "TB206-001 available for out-licensing...Twist Bioscience Corporation...announced the publication of a study detailing the discovery of TB206-001, a first-in-class antibody targeting adenosine A₂A receptor (A₂AR), a promising molecular target that could enhance cancer immunotherapy....The result was TB206-001, which directly targets A₂AR and activates immune cells. In preclinical studies, the antibody has shown high affinity and specific activity for A₂AR over other adenosine receptors and shows tumor-suppressing activity in colon tumor-bearing HuCD34-NCG mice. Additional studies in animal models found that TB206-001 reduced tumor volume better than PD-1 inhibitors."

Licensing / partnership • Preclinical • Oncology • Solid Tumor